Bhanu Chandra Mulukutla
Bhanu Chandra Mulukutla has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Cameron Harrington
Upstream Process Development Biotherapeutics Pharm. Sci., Pfizer Inc. Andover Massachusetts USA
5 shared publicationsTaylor Kalomeris
Cell Culture Process Development Pfizer Inc Andover Massachusetts USA
4 shared publicationsGregory W. Hiller
Cell Culture Process Development Pfizer Inc Andover Massachusetts USA
3 shared publicationsMichaela Jacobs
Cell Culture Process Development Pfizer Inc Andover Massachusetts USA
3 shared publicationsAparajita Dasgupta
Manufacturing Sciences and Technology Pfizer Global Supply Andover Massachusetts USA
2 shared publicationsCarolyn Huang
Bioprocess Research and Development Pfizer Research and Development Andover Massachusetts USA
2 shared publications
Latest Publications
- 15 September 2026
- Published by Wiley in Biotechnology Progress
BioOps : Enabling MLOps for scalable and flexible modelâcentric process control in biopharmaceutical development
The deployment of advanced modeling and machine learning in biopharmaceutical process control has been limited by legacy fragmented automation infrastructure and a lack of model lifecycle governance. We present BioOps, a modular automation framework for biopharmaceutical advanced process control (APC). The framework incorporates established Machine Learning Operations (MLOps) principles, including versionâcontrolled model registries, containerized deployment, and continuous integration/continuous delivery (CI/CD) pipelines. BioOps explicitly decouples model development from model execution within the control architecture. This decoupling enables process scientists to deploy, test, and iteratively refine mathematical models and control strategies in a flexible manner. These workflows can be applied across heterogeneous bioreactor platforms and are executed entirely inâhouse, without reliance on vendorâspecific solutions or custom system integration. In addition, BioOps embeds traceability, auditability, and model lifecycle management directly into the control stack. As a result, the framework aligns with regulatory expectations while continuing to support agile, inâhouse experimentation and development. Case studies across a geographically distributed set of bioreactors demonstrate BioOps' versatility in PATâdriven feedback control, hybrid modelâbased nutrient and glucose feeding, adaptive phase transitions, and crossâscale deployment. By operationalizing modelâcentric control through an MLOpsâinspired architecture, BioOps provides a practical foundation for scalable, reproducible, and futureâready biomanufacturing.
- 15 September 2026
- Published by Wiley in Biotechnology Progress
BioOps : Enabling MLOps for scalable and flexible modelâcentric process control in biopharmaceutical development
The deployment of advanced modeling and machine learning in biopharmaceutical process control has been limited by legacy fragmented automation infrastructure and a lack of model lifecycle governance. We present BioOps, a modular automation framework for biopharmaceutical advanced process control (APC). The framework incorporates established Machine Learning Operations (MLOps) principles, including versionâcontrolled model registries, containerized deployment, and continuous integration/continuous delivery (CI/CD) pipelines. BioOps explicitly decouples model development from model execution within the control architecture. This decoupling enables process scientists to deploy, test, and iteratively refine mathematical models and control strategies in a flexible manner. These workflows can be applied across heterogeneous bioreactor platforms and are executed entirely inâhouse, without reliance on vendorâspecific solutions or custom system integration. In addition, BioOps embeds traceability, auditability, and model lifecycle management directly into the control stack. As a result, the framework aligns with regulatory expectations while continuing to support agile, inâhouse experimentation and development. Case studies across a geographically distributed set of bioreactors demonstrate BioOps' versatility in PATâdriven feedback control, hybrid modelâbased nutrient and glucose feeding, adaptive phase transitions, and crossâscale deployment. By operationalizing modelâcentric control through an MLOpsâinspired architecture, BioOps provides a practical foundation for scalable, reproducible, and futureâready biomanufacturing.
- Open Access
- 7 May 2026
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 123  (7) , 1836-1870
A Modular Mechanistic In Silico Model for In Vitro Transcription Process Yield and Product Quality Prediction
In vitro transcription (IVT) plays a critical role in the manufacture of mRNA vaccines and therapeutics. Optimizing mRNA yield and ensuring product quality, such as capping efficiency and integrity, are essential but mechanistically complex. This study presents a modular mechanistic model of the IVT process to advance scientific understanding and improve predictive capability. The IVT reaction network is decomposed into interconnected modules describing (1) initiation and capping, (2) elongation and truncation, (3) termination and readâthrough, (4) mRNA degradation, (5) magnesium pyrophosphate precipitation, and (6) enzymatic degradation of pyrophosphate. Guided by biochemical principles and experimental data, kinetic models were developed for each module, accounting for mass balances, molecular complexation, and enzyme activity, and were subsequently assembled to capture coupled IVT dynamics. Multivariate residual analysis and Shapley valueâbased sensitivity analysisâguided by domain knowledgeâwere applied to iteratively improve model fidelity. These machine learningâdriven analytics enabled the identification of key mechanisms, supported in silico experimentation, and facilitated rootâcause analysis. Combined with Gaussianâprocessâbased batch Bayesian optimization for efficient parameter estimation, this framework establishes a scalable hybrid (mechanistic + machineâlearning) modeling platform that integrates heterogeneous data, accelerates model calibration, and supports rational design and optimization of mRNA manufacturing processes.
- 7 May 2026
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 123  (7) , 1836-1870
Open AccessA Modular Mechanistic In Silico Model for In Vitro Transcription Process Yield and Product Quality Prediction
In vitro transcription (IVT) plays a critical role in the manufacture of mRNA vaccines and therapeutics. Optimizing mRNA yield and ensuring product quality, such as capping efficiency and integrity, are essential but mechanistically complex. This study presents a modular mechanistic model of the IVT process to advance scientific understanding and improve predictive capability. The IVT reaction network is decomposed into interconnected modules describing (1) initiation and capping, (2) elongation and truncation, (3) termination and readâthrough, (4) mRNA degradation, (5) magnesium pyrophosphate precipitation, and (6) enzymatic degradation of pyrophosphate. Guided by biochemical principles and experimental data, kinetic models were developed for each module, accounting for mass balances, molecular complexation, and enzyme activity, and were subsequently assembled to capture coupled IVT dynamics. Multivariate residual analysis and Shapley valueâbased sensitivity analysisâguided by domain knowledgeâwere applied to iteratively improve model fidelity. These machine learningâdriven analytics enabled the identification of key mechanisms, supported in silico experimentation, and facilitated rootâcause analysis. Combined with Gaussianâprocessâbased batch Bayesian optimization for efficient parameter estimation, this framework establishes a scalable hybrid (mechanistic + machineâlearning) modeling platform that integrates heterogeneous data, accelerates model calibration, and supports rational design and optimization of mRNA manufacturing processes.
- Open Access
A Modular Mechanistic In Silico Model for In Vitro Transcription Process Yield and Product Quality Prediction
In vitro transcription (IVT) plays a critical role in the manufacture of mRNA vaccines and therapeutics. Optimizing mRNA yield and ensuring product quality, such as capping efficiency and integrity, are essential but mechanistically complex. This study presents a modular mechanistic model of the IVT process to advance scientific understanding and improve predictive capability. The IVT reaction network is decomposed into interconnected modules describing (1) initiation and capping, (2) elongation and truncation, (3) termination and read-through, (4) mRNA degradation, (5) magnesium pyrophosphate precipitation, and (6) enzymatic degradation of pyrophosphate. Guided by biochemical principles and experimental data, kinetic models were developed for each module, accounting for mass balances, molecular complexation, and enzyme activity, and were subsequently assembled to capture coupled IVT dynamics. Multivariate residual analysis and Shapley value-based sensitivity analysis, guided by domain knowledge, were applied to iteratively improve model fidelity. These machine learning-driven analytics enabled identification of key mechanisms, supported in silico experimentation, and facilitated root-cause analysis. Combined with Gaussian-process-based batch Bayesian optimization for efficient parameter estimation, this framework establishes a scalable hybrid (mechanistic + machine learning) modeling platform that integrates heterogeneous data, accelerates model calibration, and supports rational design and optimization of mRNA manufacturing processes.
Open AccessA Modular Mechanistic In Silico Model for In Vitro Transcription Process Yield and Product Quality Prediction
In vitro transcription (IVT) plays a critical role in the manufacture of mRNA vaccines and therapeutics. Optimizing mRNA yield and ensuring product quality, such as capping efficiency and integrity, are essential but mechanistically complex. This study presents a modular mechanistic model of the IVT process to advance scientific understanding and improve predictive capability. The IVT reaction network is decomposed into interconnected modules describing (1) initiation and capping, (2) elongation and truncation, (3) termination and read-through, (4) mRNA degradation, (5) magnesium pyrophosphate precipitation, and (6) enzymatic degradation of pyrophosphate. Guided by biochemical principles and experimental data, kinetic models were developed for each module, accounting for mass balances, molecular complexation, and enzyme activity, and were subsequently assembled to capture coupled IVT dynamics. Multivariate residual analysis and Shapley value-based sensitivity analysis, guided by domain knowledge, were applied to iteratively improve model fidelity. These machine learning-driven analytics enabled identification of key mechanisms, supported in silico experimentation, and facilitated root-cause analysis. Combined with Gaussian-process-based batch Bayesian optimization for efficient parameter estimation, this framework establishes a scalable hybrid (mechanistic + machine learning) modeling platform that integrates heterogeneous data, accelerates model calibration, and supports rational design and optimization of mRNA manufacturing processes.
- 19 August 2025
- Published by Wiley in Biotechnology Journal
- Vol. 20  (8) , e70087
Uncovering GrowthâInhibitory Metabolic Byproducts in HEK293 FedâBatch Cultures and Strategies for Their Control
Human Embryonic Kidney 293 (HEK293) cells are currently one of the preferred host cell lines for the production of biologics, specifically, AAVâbased viral vectors. These fastâgrowing cells consume significant amounts of nutrients and often convert them into byproducts such as lactate and ammonia. In fedâbatch cultures, accumulation of lactate and ammonia to high levels can inhibit cell proliferation. In this study, we demonstrate that lactate and ammonia accumulation alone doesn't fully explain the growth inhibition observed in HEK293 fedâbatch cultures. Growth inhibition was noted even when the residual levels of these byproducts were well controlled. Instead, we show that several previously unknown compounds accumulate in HEK293 cell fedâbatch cultures, some of which can inhibit HEK293 cell growth either individually or synergistically. Many of these newly identified compounds are intermediates or byproducts of amino acid catabolism. When residual levels of the source amino acids for these novel byproducts were controlled in the low concentration range (âź1 mM) in HEK293 fedâbatch cultures, lactate accumulated to higher levels, causing growth inhibition. This prompted the use of Highâend pH Delivery of Glucose (HIPDOG), a control strategy that limits lactate production by keeping low residual concentrations of glucose. In HIPDOG cultures, controlling the source amino acids at low concentrations resulted in lower accumulations of the corresponding growthâinhibitory byproducts when compared to the control HIPDOG conditions with typical levels of amino acids. This led to higher viable cell densities (VCD) and viabilities in low amino acid conditions. Strategies that reduce byproduct accumulation, whether classical or novel byproducts, in HEK293 fedâbatch processes can result in enhanced VCDs, potentially leading to higher volumetric productivities.
- 19 August 2025
- Published by Wiley in Biotechnology Journal
- Vol. 20  (8) , e70087
Uncovering GrowthâInhibitory Metabolic Byproducts in HEK293 FedâBatch Cultures and Strategies for Their Control
Human Embryonic Kidney 293 (HEK293) cells are currently one of the preferred host cell lines for the production of biologics, specifically, AAVâbased viral vectors. These fastâgrowing cells consume significant amounts of nutrients and often convert them into byproducts such as lactate and ammonia. In fedâbatch cultures, accumulation of lactate and ammonia to high levels can inhibit cell proliferation. In this study, we demonstrate that lactate and ammonia accumulation alone doesn't fully explain the growth inhibition observed in HEK293 fedâbatch cultures. Growth inhibition was noted even when the residual levels of these byproducts were well controlled. Instead, we show that several previously unknown compounds accumulate in HEK293 cell fedâbatch cultures, some of which can inhibit HEK293 cell growth either individually or synergistically. Many of these newly identified compounds are intermediates or byproducts of amino acid catabolism. When residual levels of the source amino acids for these novel byproducts were controlled in the low concentration range (âź1 mM) in HEK293 fedâbatch cultures, lactate accumulated to higher levels, causing growth inhibition. This prompted the use of Highâend pH Delivery of Glucose (HIPDOG), a control strategy that limits lactate production by keeping low residual concentrations of glucose. In HIPDOG cultures, controlling the source amino acids at low concentrations resulted in lower accumulations of the corresponding growthâinhibitory byproducts when compared to the control HIPDOG conditions with typical levels of amino acids. This led to higher viable cell densities (VCD) and viabilities in low amino acid conditions. Strategies that reduce byproduct accumulation, whether classical or novel byproducts, in HEK293 fedâbatch processes can result in enhanced VCDs, potentially leading to higher volumetric productivities.
- Open Access
- 19 February 2025
- Published by Wiley
Digging deeper into HEK293 metabolism: Growth inhibitory metabolic byproduct production in fed-batch cultures and their control
Not-yet-known not-yet-known not-yet-known unknown Human Embryonic Kidney 293 (HEK293) cells are currently one of the preferred host cell lines for production of biologics, specifically, AAVâbased viral vectors. These fast-growing cells consume significant amounts of nutrients and often convert them into byproducts such as lactate and ammonia. In fed-batch cultures, accumulation of lactate and ammonia to high levels can inhibit cell proliferation. In this study, we demonstrate that lactate and ammonia accumulation alone doesnât fully explain the growth inhibition observed in HEK293 fed-batch cultures. Growth inhibition was noted even when the levels of these byproducts were well controlled. Instead, we show that several previously unknown compounds accumulate in HEK293 cell fed-batch cultures, some of which can inhibit HEK293 cell growth either individually or synergistically. Many of these newly identified compounds are intermediates or byproducts of amino acid catabolism. When residual levels of the source amino acids for these novel byproducts were controlled in the low concentration range (~1mM) in HEK293 fed-batch cultures, lactate accumulated to higher levels, causing growth inhibition. This prompted the need for employing HIPDOG control strategy for lactate management. In HIPDOG cultures, controlling the source amino acids at low concentrations resulted in lower accumulations of the corresponding growth-inhibitory byproducts when compared to the control HIPDOG conditions with typical levels of amino acids. This led to higher viable cell densities (VCD) and viabilities in low amino acid conditions. Strategies that reduce byproduct accumulation, whether classical or novel byproducts, in HEK293 fed-batch processes can result in enhanced VCDs potentially leading to higher volumetric productivities
- 19 February 2025
- Published by Wiley
Open AccessDigging deeper into HEK293 metabolism: Growth inhibitory metabolic byproduct production in fed-batch cultures and their control
Not-yet-known not-yet-known not-yet-known unknown Human Embryonic Kidney 293 (HEK293) cells are currently one of the preferred host cell lines for production of biologics, specifically, AAVâbased viral vectors. These fast-growing cells consume significant amounts of nutrients and often convert them into byproducts such as lactate and ammonia. In fed-batch cultures, accumulation of lactate and ammonia to high levels can inhibit cell proliferation. In this study, we demonstrate that lactate and ammonia accumulation alone doesnât fully explain the growth inhibition observed in HEK293 fed-batch cultures. Growth inhibition was noted even when the levels of these byproducts were well controlled. Instead, we show that several previously unknown compounds accumulate in HEK293 cell fed-batch cultures, some of which can inhibit HEK293 cell growth either individually or synergistically. Many of these newly identified compounds are intermediates or byproducts of amino acid catabolism. When residual levels of the source amino acids for these novel byproducts were controlled in the low concentration range (~1mM) in HEK293 fed-batch cultures, lactate accumulated to higher levels, causing growth inhibition. This prompted the need for employing HIPDOG control strategy for lactate management. In HIPDOG cultures, controlling the source amino acids at low concentrations resulted in lower accumulations of the corresponding growth-inhibitory byproducts when compared to the control HIPDOG conditions with typical levels of amino acids. This led to higher viable cell densities (VCD) and viabilities in low amino acid conditions. Strategies that reduce byproduct accumulation, whether classical or novel byproducts, in HEK293 fed-batch processes can result in enhanced VCDs potentially leading to higher volumetric productivities
- 20 June 2024
- Published by Elsevier in Metabolic Engineering
- Vol. 84, 128-144
Metabolic engineering of CHO cells towards cysteine prototrophy and systems analysis of the ensuing phenotype
- 20 June 2024
- Published by Elsevier in Metabolic Engineering
- Vol. 84, 128-144
Metabolic engineering of CHO cells towards cysteine prototrophy and systems analysis of the ensuing phenotype
- 27 September 2021
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 118  (12) , 4786-4799
Production of butyrate and branchedâchain amino acid catabolic byproducts by CHO cells in fedâbatch culture enhances their specific productivity
Chinese hamster ovary (CHO) cells in fedâbatch cultures produce several metabolic byproducts derived from amino acid catabolism, some of which accumulate to growth inhibitory levels. Controlling the accumulation of these byproducts has been shown to significantly enhance cell proliferation. Interestingly, some of these byproducts have physiological roles that go beyond inhibition of cell proliferation. In this study, we show that, in CHO cell fedâbatch cultures, branchedâchain amino acid (BCAA) catabolism contributes to the formation of butyrate, a novel byproduct that is also a wellâestablished specific productivity enhancer. We further show that other byproducts of BCAA catabolism, namely isovalerate and isobutyrate, which accumulate in CHO cell fedâbatch cultures, also enhance specific productivity. Lastly, we show that the rate of production of these BCAA catabolic byproducts is negatively correlated with glucose uptake and lactate production rates. Thus, limiting glucose supply to suppress glucose uptake and lactate production, as in the case of fedâbatch cultures employing highâend pHâcontrolled delivery of glucose (HiPDOG) technology, significantly enhances BCAA catabolic byproduct accumulation, resulting in higher specific productivities.
- 27 September 2021
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 118  (12) , 4786-4799
Production of butyrate and branchedâchain amino acid catabolic byproducts by CHO cells in fedâbatch culture enhances their specific productivity
Chinese hamster ovary (CHO) cells in fedâbatch cultures produce several metabolic byproducts derived from amino acid catabolism, some of which accumulate to growth inhibitory levels. Controlling the accumulation of these byproducts has been shown to significantly enhance cell proliferation. Interestingly, some of these byproducts have physiological roles that go beyond inhibition of cell proliferation. In this study, we show that, in CHO cell fedâbatch cultures, branchedâchain amino acid (BCAA) catabolism contributes to the formation of butyrate, a novel byproduct that is also a wellâestablished specific productivity enhancer. We further show that other byproducts of BCAA catabolism, namely isovalerate and isobutyrate, which accumulate in CHO cell fedâbatch cultures, also enhance specific productivity. Lastly, we show that the rate of production of these BCAA catabolic byproducts is negatively correlated with glucose uptake and lactate production rates. Thus, limiting glucose supply to suppress glucose uptake and lactate production, as in the case of fedâbatch cultures employing highâend pHâcontrolled delivery of glucose (HiPDOG) technology, significantly enhances BCAA catabolic byproduct accumulation, resulting in higher specific productivities.
- Open Access
- 11 February 2021
- Published by Wiley
Production of Butyrate and Branched Chain Amino Acid Catabolic Byproducts by CHO Cells in Fed-batch Culture Enhances their Specific Productivity
Chinese hamster ovary (CHO) cells in fed-batch cultures produce several metabolic byproducts derived from amino acid catabolism, some of which accumulate to growth inhibitory levels. Controlling the accumulation of these byproducts has been shown to significantly enhance cell proliferation. Interestingly, some of these byproducts have physiological roles that go beyond inhibition of cell proliferation. In this study, we show that, in CHO cell fed-batch cultures, branched chain amino acid (BCAA) catabolism contributes to the formation of butyrate, a novel byproduct that is also a well-established specific productivity enhancer. Further, the other byproducts of BCAA catabolism, isovalerate and isobutyrate, which accumulate in CHO cell fed-batch cultures also enhance specific productivity. Additionally, the rate of production of these BCAA catabolic byproducts was negatively correlated with glucose uptake and lactate production rates. Limiting glucose supply to suppress glucose uptake and lactate production, like in case of fed-batch cultures employing HiPDOG technology, significantly enhances BCAA catabolic byproduct accumulation resulting in higher specific productivities.
- 11 February 2021
- Published by Wiley
Open AccessProduction of Butyrate and Branched Chain Amino Acid Catabolic Byproducts by CHO Cells in Fed-batch Culture Enhances their Specific Productivity
Chinese hamster ovary (CHO) cells in fed-batch cultures produce several metabolic byproducts derived from amino acid catabolism, some of which accumulate to growth inhibitory levels. Controlling the accumulation of these byproducts has been shown to significantly enhance cell proliferation. Interestingly, some of these byproducts have physiological roles that go beyond inhibition of cell proliferation. In this study, we show that, in CHO cell fed-batch cultures, branched chain amino acid (BCAA) catabolism contributes to the formation of butyrate, a novel byproduct that is also a well-established specific productivity enhancer. Further, the other byproducts of BCAA catabolism, isovalerate and isobutyrate, which accumulate in CHO cell fed-batch cultures also enhance specific productivity. Additionally, the rate of production of these BCAA catabolic byproducts was negatively correlated with glucose uptake and lactate production rates. Limiting glucose supply to suppress glucose uptake and lactate production, like in case of fed-batch cultures employing HiPDOG technology, significantly enhances BCAA catabolic byproduct accumulation resulting in higher specific productivities.
- Open Access
- 18 January 2021
- Published by Wiley
Lactate Control Enhances Growth Advantage in Fed-batch Cultures of Metabolically Engineered CHO Cells with Reduced Novel Growth-inhibitory Compound Formation
CHO cells have been recently shown to produce amino acid catabolism derived byproducts, which accumulate in fed-batch cultures to growth-inhibitory levels. Residual amino acid limitation or genetic engineering strategies have been successfully employed to suppress production of these novel growth inhibitory metabolic byproducts. However, the growth advantage attained due to suppression of these metabolic byproducts in fed-batch cultures is more pronounced when lactate accumulation is also controlled. BCAT1 knock-out (KO) CHO cells, which produce negligible levels of the metabolic byproducts isovalerate, isobutyrate and 2-methylbutyrate, grow to significantly higher peak cell densities in fed-batch cultures with lactate control (HiPDOG) as compared to cultures without lactate control. Henceforth, strategies involving novel metabolic byproduct control should preferably include lactate control to more easily assess the enhanced cell growth and productivities attainable.
- 18 January 2021
- Published by Wiley
Open AccessLactate Control Enhances Growth Advantage in Fed-batch Cultures of Metabolically Engineered CHO Cells with Reduced Novel Growth-inhibitory Compound Formation
CHO cells have been recently shown to produce amino acid catabolism derived byproducts, which accumulate in fed-batch cultures to growth-inhibitory levels. Residual amino acid limitation or genetic engineering strategies have been successfully employed to suppress production of these novel growth inhibitory metabolic byproducts. However, the growth advantage attained due to suppression of these metabolic byproducts in fed-batch cultures is more pronounced when lactate accumulation is also controlled. BCAT1 knock-out (KO) CHO cells, which produce negligible levels of the metabolic byproducts isovalerate, isobutyrate and 2-methylbutyrate, grow to significantly higher peak cell densities in fed-batch cultures with lactate control (HiPDOG) as compared to cultures without lactate control. Henceforth, strategies involving novel metabolic byproduct control should preferably include lactate control to more easily assess the enhanced cell growth and productivities attainable.
- 1 July 2019
- Published by Elsevier in Metabolic Engineering
- Vol. 54, 54-68
Metabolic engineering of Chinese hamster ovary cells towards reduced biosynthesis and accumulation of novel growth inhibitors in fed-batch cultures
- 1 July 2019
- Published by Elsevier in Metabolic Engineering
- Vol. 54, 54-68
Metabolic engineering of Chinese hamster ovary cells towards reduced biosynthesis and accumulation of novel growth inhibitors in fed-batch cultures